Immerse yourself in a comprehensive analysis with this report on the Coronary Artery Disease Therapeutics Market. This forecast is critical for senior executives looking to stay ahead in an evolving global healthcare environment. It unearths valuable insights to underline the potential of the market, which is primarily driven by the surge in the prevalence of coronary artery disease across the globe, increasing investment in the development of therapeutics, and the rising geriatric population.
Further insights reveal compelling trends in the market such as the significance of statins as a first-line treatment, presenting opportunities for substantial growth. The report also provides a detailed territorial breakdown which indicates North America as a region of high market share, given its ageing population, increasing incidence of coronary artery disease and strong presence of major market players. Keep abreast with the rapidly changing landscape of coronary artery disease therapeutics and confidently steer your business towards informed decisions and profitable results.
The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cardiovascular diseases to significant risks. Similarly, the demand for coronary artery disease drugs was significantly impacted during the pandemic owing to the increased risk of COVID-19 infection among patients with cardiovascular diseases. A study published in the Frontiers in Medicine in December 2021 indicated that despite having Coronary artery Disease (CAD) symptoms, 9.1% of patients did not see a medical practitioner due to fear of becoming infected with COVID-19. This led to a decline in market growth initially during the pandemic due to a decrease in the diagnosis of coronary artery disease and the lack of adoption of CAD therapeutics due to stringent lockdowns, supply chain restrictions, and production shutdowns. In the late pandemic, there has been an incline in the market growth of CAD therapeutics due to the rising adoption of CAD therapeutics in COVID-19 patients. For instance, according to the extensive research presented at the American Society of Anesthesiologists annual meeting in October 2022, high cholesterol was treated with statins by 30% of the 38,875 patients hospitalized for COVID-19 at 185 hospitals in the United States between January 1 and September 30, 2020, and found that statin users had a 37 percent lower COVID-19 mortality rate than non-users. In the late pandemic phase, there has been a positive impact on market growth due to the rise in the adoption of statins in COVID-19 patients.
The market is primarily driven by the surge in the prevalence of coronary artery disease across the globe, increasing investment in research and development of coronary artery disease therapeutics, and rising comorbidities such as atherosclerosis and hypertension. The geriatric population is expected to significantly impact the market studied, as people over 65 are more prone to chronic diseases. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. By 2050, 80% of the world's elderly will live in low- and middle-income countries. The population is aging at a much faster rate than in the past. According to the British Heart Foundation, in August 2022, Coronary heart disease (CHD) will be the most common type of heart, and circulatory disease in the UK, and 2.3 million people will be living with CHD in 2021. Thus, the high burden of coronary heart disease is expected to increase the demand for its management, thereby contributing to the growth of the market.
Furthermore, growing incidence and prevalence rates of hypertension, high cholesterol, diabetes, and obesity across the world, government initiatives to increase awareness of the disease, and increasing investment in research and development activity are the key driving factors in the coronary artery disease therapeutics market. For instance, according to the National Institute of Health (NIH) 2022, the estimated NIH funding for Coronary Heart Diseases in 2021 and 2022 is USD 380 million and USD 395 million, respectively. Therefore, the rising funding for CAD will lead to increased research on CAD therapies, thereby leading to innovative therapies' development and market growth.
In addition, rising initiatives from the key market players are also expected to drive market growth over the forecast period. For instance, in December 2021, Novartis entered a commercial agreement with the NHS in England to address elevated LDL-C in eligible patients with coronary artery diseases across England. With this collaboration, the NHS and Novartis move into the implementation phase following the positive final recommendation from the National Institute for Health and Care Excellence (NICE) for the use of inclisiran in primary care for the treatment of adult patients with CAD. Such initiatives are expected to drive market growth due to the rise in the adoption of inclisiran in CAD in developed countries such as the UK.
Therefore, the rising prevalence of CAD, rising initiatives from the market players, the rising geriatric population, and rising research on CAD therapeutics are the factors expected to drive market growth. However, the high cost of treatment, limited awareness, and unavailability of proper healthcare infrastructure for therapeutics may restrain the market growth over the forecast period.
Coronary Artery Disease Therapeutics Market Trends
Statins Segment is Expected to Hold a Significant Market Share in the Coronary Artery Disease Therapeutics Market Over the Forecast Period.Statin medications are drugs that help to lower cholesterol levels in the blood and prevent coronary heart disease. Statins are the first-line treatment of choice for patients with coronary heart disease and high cholesterol levels. These drugs have additional benefits such as improvements in endothelial function, reduction in the amount of inflammation and damage done to cells through oxidation stress, and prevention of platelet aggregation, thereby reducing the risk of a blood clot (thrombus).
The statins segment holds a significant market share in the coronary artery disease therapeutics market. It is anticipated to show a similar trend over the forecast period due to its ability to reduce mortality and cardiovascular events in patients with coronary artery disease or at high risk of cardiovascular disease. According to the study published in the Journal of Cardiothoracic Imaging in April 2022, baseline statin medication was related to a reduction in major cardiovascular events in people with non-obstructive coronary artery disease (CAD). Statins act by lowering levels of low-density lipoprotein cholesterol, reducing the substrate for plaque formation, and can also stabilize plaques by favorably changing the plaque pathophysiology. Thus, the above benefits of statin therapy in the CAD are expected to increase demand for statins, thereby boosting segment growth.
Moreover, rising approvals of the statins are further expected to boost the market growth. For instance, in March 2021, the FDA approved Althera Pharmaceutical's Roszet (rosuvastatin/ezetimibe) in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C). Such approvals are anticipated to drive segment growth due to the rise in the adoption of statins.
Therefore, the rising approvals of statins and the importance of statins as a first-line treatment in the management of CAD are the factors expected to drive segment growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast PeriodNorth America is expected to hold a major market share in the global coronary artery disease therapeutics market due to the growing geriatric population, strong foothold of major market players, and increasing incidences of coronary artery disease.
The rising prevalence of coronary artery disease in the United States is expected to drive the growth of the market studied in the region. For instance, according to CDC, in 2022, the percentage of coronary heart disease for adults aged 18 and over in the United States 2021 is 4.9%. Such a huge prevalence is anticipated to drive market growth due to the rising adoption of therapies in these patients.
Moreover, continuous product approval in the segment is expected to drive segment growth. For instance, in August 2021, Health Canada approved MYINFLA 0.5 mg for the reduction of cardiovascular risk in patients with coronary disease. In addition, in February 2022, FDA approved Norliqva (amlodipine) oral solution for the treatment of hypertension in adults and children 6 years and older and coronary artery disease. Thus, such advances in the region are anticipated to drive market growth over the forecast period.
Thus, the market is expected to witness a high growth rate over the forecast period due to the factors mentioned above in the North American region. Furthermore, high healthcare spending and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
Coronary Artery Disease Therapeutics Market Competitor AnalysisThe Coronary Artery Disease Therapeutics Market is moderately fragmented and consists of several major players. The competition is driven by the rise in product launches, the rise in partnerships among hospitals and drug developers, and increasing research for the development of novel therapies. Some of the companies which are operating in the market are AstraZeneca Plc, Novartis AG, Pfizer Inc, Bayer AG, Bristol-Myers Squibb Company, Kowa Pharmaceuticals America, Inc., Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Viatris Inc (Mylan N.V.)
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Surge in Prevalence of Coronary Artery Disease Across the Globe
4.2.2 Increasing Investment on R&D of Coronary Artery Disease Therapeutics
4.2.3 Rising Comorbidities such as Atherosclerosis and Hypertension
4.3 Market Restraints
4.3.1 High Costs of Treatment
4.3.2 Limited Awareness and Unavailability of Proper Healthcare Infrastructure for the Therapeutics
4.4 Porter Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.3 Calcium Channel Blockers
5.1.4 ACE Inhibitors
5.1.5 Antiplatelet Drugs
5.2 By Distribution Channel
5.2.2 Online Pharmacies
5.2.3 Retail Pharmacies
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6.1.1 AstraZeneca Plc
6.1.2 Covis Pharma GmbH
6.1.3 Novartis AG
6.1.4 Pfizer Inc
6.1.5 Bayer AG
6.1.6 Bristol-Myers Squibb Company
6.1.7 Kowa Pharmaceuticals America, Inc.
6.1.8 Merck & Co. Inc
6.1.9 Teva Pharmaceutical Industries Ltd
6.1.10 Viatris (Mylan N.V.)
6.1.12 Rosemont Pharmaceuticals
A selection of companies mentioned in this report includes:
- AstraZeneca Plc
- Covis Pharma GmbH
- Novartis AG
- Pfizer Inc
- Bayer AG
- Bristol-Myers Squibb Company
- Kowa Pharmaceuticals America, Inc.
- Merck & Co., Inc
- Teva Pharmaceutical Industries Ltd
- Viatris (Mylan N.V.)
- Rosemont Pharmaceuticals